Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292809 · ClinicalTrials.gov registry record · Phase 2
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2 study, sponsored by Novaliq.
- Completed
- Registry status
- Phase 2
- Development phase
- 328
- Enrollment target
NCT03292809: Completed Phase 2 study, sponsored by Novaliq.
NCT03292809 is a Phase 2 study that has completed, run by Novaliq. The registered enrollment target is 328 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03292809, a Phase 2 study, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 328 participants
- Enrollment target
Study Summary
The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
Primary Outcome
CFS was assessed in each eye using the National Eye Institute (NEI) scale. A standardized grading system of 0-3 is used for each of the five areas on each cornea. Grade 0 will be specified when no staining is present. The maximum total score for each eye is 15. Higher values describe greater staining and corneal damage.
Interventions
- DRUG CyclASol topical ocular, eye drops
- DRUG Vehicle topical ocular, eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2018-06-20 |
| Phase | Phase 2 |
What the finished NCT03292809 record still lists
NCT03292809 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 2 interventions - of which CyclASol topical ocular, eye drops is the first listed.
NCT03292809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03292809 about?
NCT03292809 is a clinical study titled "CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)". The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
What is the current status of trial NCT03292809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 328 participants. The study started on 2017-10-19. Estimated completion is 2018-06-20.
What interventions are being tested in trial NCT03292809?
The interventions under investigation include: CyclASol topical ocular, eye drops (DRUG), Vehicle topical ocular, eye drops (DRUG).
Who is sponsoring clinical trial NCT03292809?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03292809's enrollment target sits among peer trials
328 146th of 2000 higher than 1,855 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
- NCT05548413 · 328 participants · NA
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
- NCT06393725 · 328 participants · NA
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI